Doxorubicin is a chemotherapy medication used in the treatment of various cancers, including breast cancer, bladder cancer, lung cancer, leukemia, lymphoma, and others. It belongs to the class of medications called anthracyclines and works by interfering with the growth and spread of cancer cells in the body. Several pharmaceutical companies globally produce and distribute doxorubicin under various brand names.
Jan 2024
Sun Pharmaceutical Industries Launched their Doxil® liposomal doxorubicin injection in the US market, entering the competition for this segment with a strong market share in other regions.Collaborated with research institutions to explore new applications of doxorubicin in combination therapies for treating other cancer types.
Baxter International Received FDA approval for their Doxorubicin HCl liposome injection, another player in the liposomal doxorubicin market offering healthcare providers additional options.Partnered with logistics companies to improve the distribution and availability of doxorubicin and other essential cancer drugs in underserved regions.
Venus Remedies Secured marketing authorization for doxorubicin among other chemotherapy drugs in the Philippines, expanding their reach in the Southeast Asian market.Invested in manufacturing upgrades and quality control measures to ensure consistent supply and high-quality doxorubicin production.
Padagis Pharmaceuticals Partnered with Ayana Pharma Ltd. to launch their AB-rated generic doxorubicin liposome injection in the US, increasing competition and potentially lowering costs for patients.Continued research efforts to develop next-generation drug delivery systems for doxorubicin with improved targeting and efficacy.
List of Doxorubicin Key Companies in The Market
Doxorubicin Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)